

**Toxicological Assessment of Levonorgestrel (Postinor 2) Intake in Selected Reproductive
and Vital Organs in Animal Model**

**Catherine Bosede ADENIJI
LCU/PG/002032**

**Being a PhD Thesis Submitted to the Department of Chemical Sciences, Faculty of Natural
and Applied Sciences, Lead City University, Ibadan, Oyo State, Nigeria**

**In Partial Fulfilment of the Requirements for the Award of Doctor of Philosophy (PhD) in
Environmental Biochemistry and Toxicology**

2023

Do Not Copy, Lead City University, Nigeria

Certification

This is to certify that this research was carried out and the thesis written by Catherine Bosede ADENIJI with the Matriculation number LCU/PG/002032 under my supervision as part of the requirement for PhD in Environmental Biochemistry and Toxicology, Department of Chemical Sciences, Faculty of Natural and Applied Sciences, Lead City University, Ibadan, Nigeria.

Prof. O. M Ighodaro

Professor of Biochemistry

Supervisor

Date

Prof. O. M Ighodaro

Professor of Biochemistry

Head of Department

Date

Dedication

This research work is dedicated to Tony, Jason and Charis Adeniji whose love and support constantly inspires me to dream and to dare.

Do Not Copy, Lead City University, Nigeria

Acknowledgment

I am grateful to this citadel of learning, Lead City University for creating an atmosphere for this knowledge advancement. I will like to appreciate the wonderful support and guidance I enjoyed from my supervisor, Prof. O. M. Ighodaro, a person of amiable character, a scholar per excellence, an astute teacher and seasoned researcher, whose encouraging words and thoughtful, detailed feedback ensured that I give it all it takes to finish that which I started and most importantly, in due time. My gratitude goes also to the entire staff of Chemical sciences, Lead City University who have contributed generously to my knowledge in several ways.

I will also love to express my sincere gratitude and heartily thanks to those who generously took time out of their busy schedules to participate in my research, Dr Abiola Adeosun, a passionate Biochemist and Brilliant Researcher with a heart of gold, always ready to help and teach. Saibu Oluwatosin came my way as an answer to a prayer for help, I will not be able to appreciate you enough. Also, Mr. Oyerinde, a brilliant Physiologist, Mr Austin, Shalom Okhuakhua, Adeleke Oluwadara, and Lolade Kolaru. Thank you all very kindly.

My profound appreciation goes to Mr. Gbolaga (Physiology Laboratory) for his patience and tolerance when I was working in the Physiology laboratory. I had to also use the Pharmacy laboratory and I enjoyed the hospitality of Miss Kehinde and Taiwo Bamidele, for this, I say thank you. I will also like to acknowledge the warm support of Mrs. Duyilemi of the Biochemistry Laboratory and other Technicians in the Lab. Mr. Abeeb Adeyemi of Microbiology was very helpful and resourceful, thank you so much. I am indebted to my friend, Sola Oyesusi, and my student, Ashley Chidera, for their help in administering the questionnaires, thanks a bunch. Prof Grace Oloukoi has always been supportive and concerned, so also are the Adelekes who helped in taking care of my kids, thank you very kindly.

I want to say a big thank you to my source, my parents and strength, Chief Samuel and Pastor (Mrs.) Temilola Arewa. Also, my siblings, Mrs. Opeyemi Babalola, Mrs. Bukola Akintoye and their hubbies, I am grateful for your love always. To my wonderful children, Jason Oluwaferanmi (who helped with some GraphPad designs) and Charis Oluwafifehanmi, who was always asking when I will submit this work so I can play with them. I want to say thank you for your support and love, when I count my blessings, I count you twice. I want to express my heartfelt appreciation to my amiable husband and friend, my support system and encourager. I am certain this journey was easier because you stood by me and held my hand all the way. Thank you for your patience and understanding, you are a rare gem and I am blessed to have you. My sincere gratitude goes to the Almighty God, my Stone of Help and Redeemer, for life, health, inspiration and help, I never thought I could come this far, His Grace and mercy has been my anchor.

Do Not Copy, Lead City University, Nigeria

Abstract

Increased sexual activities among adolescents have resulted in the indiscriminate use of contraceptives. This study assessed the toxicological effects of *levonorgestrel* (LNG) intake on reproductive and vital organs in a rat model. Sixty Wistar rats weighing between 110 and 120 g were randomized into three groups (n = 20). Groups A and B were administered 1.83 mg/kg BW of LNG once and twice a week respectively, and group C served as the control. Five animals from each group were sacrificed at 30, 60, and 90 days, while the last batch was left for 30 days for post-treatment recovery. The effect of LNG on the estrous cycle was assessed through physical and cytological evaluations. The uterus, ovary, liver, and kidney were investigated for possible anomalies through histopathological examination and biochemical analyses. Hormonal changes were assessed by measuring the serum levels of progesterone (P4), estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) using the ELISA technique. Effects of LNG on fertilization, implantation, and tissue inflammation were assessed by measuring progesterone-associated endometrial protein (PAEP), leukemia inhibitory factor (LIF), prolactin (PRL), sex hormone-binding globulin (SHBG), Nuclear Factor Kappa B (NF- κ B), and Tumor Necrosis Factor α (TNF- α) using ELISA. Hepatotoxicity was determined by measuring aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) using standard spectrophotometric methods. Similarly, nephrotoxicity was determined via cystatin C, urea, creatinine, BUN, and the BUN-creatinine ratio levels. Oxidative damage was assessed by determining the tissue activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD), including the concentrations of reduced glutathione (GSH) and malondialdehyde (MDA), using standard procedures. LNG prolonged the metestrus phase of the estrous cycle. Hyperplastic degeneration, disseminated congestion, and extensive tubular necrosis were found in the uterus, liver, and kidney of the treated groups. P4 was normal, LH, FSH, TNF- α , and NF- κ B were markedly elevated with LNG treatment, while E2, PAEP, LIF, PRL, and SHBG were decreased. Serum AST, ALT, ALP, GGT, Cystatin C, creatinine, and urea were significantly elevated. GSH level and CAT, GPx, and SOD activities were significantly lowered, whereas MDA level was increased. LNG treatment caused time- and dose-dependent hormonal modulation and organ toxicity. The uterus and liver were particularly affected, and animals exposed to LNG twice a week apparently suffered more assaults. The ability of the animals to recover following drug withdrawal was more evident in the once-weekly treated group, particularly with respect to hormonal, liver, and kidney aberrations.

Keywords: *Levonorgestrel*, estrus cycle, uterus, ovary, hormonal imbalance

Word Count: 402

Table of Contents

Content	Page
Title Page	i
Certification	ii
Dedication	iii
Acknowledgment	iv
Abstract	vi
Table of Contents	vii
List of Tables	xx
List of Figures	xxi
List of Plates	xxvii
List of Acronyms	xxix
Chapter One: Introduction	
1.1 Background to the Study	1
1.2 Statement of the Problem	6
1.3 Justification of the Study	7
1.4 Aim and Objectives of the Study	8
1.5 Specific Objectives	8
1.5 Significance of the Study	10
1.6 Scope of the Study	10
1.7 Limitation of the Study	11
1.8 Operational Definition of Terms	11

Endnotes	13
-----------------	----

Chapter Two: Literature Review

2.1	Increased Sexual Activities among Young Adults	21
2.2	Impact of Unwanted Pregnancy and Unsafe Abortion	22
2.3	Emergency Contraceptive Pills (ECPs)	23
2.3.1	Brief History of ECPs	24
2.3.2	Lack of Adequate Information on ECPs	26
2.3.3	When to Use ECPs	30
2.3.4	Effectiveness of ECPs	31
2.3.5	Mode of Action of ECPs	35
2.3.6	Potential Toxicity of ECPs	35
2.3.7	Types of ECPs	37
2.3.7.1	Levonorgestrel	37
2.3.7.2	Mechanism of Action of LNG	39
2.3.7.3	Postinor 2 (Levonorgestrel 0.75 mg and 1.5 mg)	40
2.3.7.4	Pharmacology and Pharmacokinetics of LNG	44
2.3.7.5	Metabolism of LNG	44
2.3.7.6	Distribution Volume of Levonorgestrel	45
2.3.7.7	Binding of Levonorgestrel to Protein	45
2.3.7.8	Drug-Drug Interactions and Contraindications of LNG	46
2.3.7.9	Route of Levonorgestrel Elimination	46
2.3.8	Other Forms of ECPs	47
2.3.8.1	Ulipristal Acetate (UPA)	47

2.3.8.1.1	Pharmacokinetics and Pharmacodynamics of UPA	49
2.3.8.1.2	Effect of UPA on the Reproductive Organs	52
2.3.8.1.3	Metabolism of UPA	54
2.3.8.1.4	Biotransformation/Elimination of UPA	56
2.3.8.2	Ethinylestradiol (EE)	56
2.3.8.2.1	Pharmacology and Pharmacokinetics of Ethinyl Estradiol	57
2.3.8.2.2	Toxicity of Ethinylestradiol	59
2.3.8.3	Combined Oral Contraceptives (COCs)	60
2.4	The Female Reproductive System	61
2.4.1	The Ovaries	63
2.4.1.1	The Menstrual Cycle	63
2.4.1.2	Effects of LNG on the Menstrual Cycle	65
2.4.2	The Fallopian Tubes	67
2.4.2.1	Effects of LNG on the Fallopian Tubes	69
2.4.3	The Uterus	70
2.4.3.1	Effect of LNG on the Uterus	71
2.5	Implantation	75
2.5.1	The Process of Implantation	75
2.5.2	Stages of Implantation	78
2.5.2.1	Apposition and Adhesion	78
2.5.2.2	Invasion	79
2.5.3	Biological Factors that Mediates Implantation	80
2.5.3.1	Hormones	80

2.5.3.1.1	Estrogen	80
2.5.3.1.2	Progesterone	83
2.5.3.1.3	Effects of Hormonal Modulation on Implantation	85
2.5.3.2	Cytokines	86
2.5.3.3	Leukemia Inhibitory Factor (LIF)	87
2.5.3.3.1	Effect of LNG on Uterine Leukemia Inhibitory Factor (LIF)	88
2.5.3.4	Growth Factors	89
2.6.1	Hormones of Importance in the Reproductive Tract	91
2.6.1.1	Luteinizing Hormone (LH)	91
2.6.1.2	Follicle Stimulating Hormone (FSH)	93
2.6.1.3	Biochemical Profile and Synergistic Action of LH and FSH	96
2.6.2	Hormonal Modulation and Infertility	97
2.6.2	The Rats' Estrus Cycle	98
2.7.1	The Proestrus Phase	99
2.6.3	The Estrus Phase	99
2.6.4	The Metestrus Phase	99
2.6.5	The Diestrus Phase	100
	Endnotes	101
	Chapter Three: Methodology	
3.1	Study Design	120
3.2	Administration of Questionnaires	120
3.2.1	Analysis of Questionnaires	120
3.3	Study Area	120

3.4	Drug Procurement	120
3.5	Drug Dosage Determination and Drug Dilution	121
3.6	Experimental Animals	121
3.7	Experimental Design	121
3.8	Determination of Body Weight of Rats	124
3.9	Physical Observation of the Experimental Model before, during and after Treatments	124
3.10	Identification of the Effect of Postinor 2 Treatment on the Rats Estrous Cycle	124
3.10.1	Visual Assessment of the Estrous Cycle to observe Effect of Postinor 2 Treatment	124
3.10.2	Determination of the Effect of Postinor 2 on the Estrus Cycle of Rats through Cytological Evaluation	124
3.11	Sacrifice of Experimental Animals and Harvest of Organs	126
3.12	Homogenization and Centrifugation	126
3.13	Histopathological Examination of Tissues	127
3.13.1	Protocol for the Processing of Tissues	127
3.13.2	Heamatoxylin and Eosin Staining	127
3.13.3	Microscopic Examination	127
3.14	Assessment of Sex Hormones	128
3.14.1	Quantitative Determination of Progesterone (P4)	128
3.14.1.1	Principle of P4 Determination	128
3.14.1.2	Reagents for P4 Determination	129
3.14.1.3	Procedure for P4 Determination	129
3.14.1.4	Calculation of P4 Assay Results	130

3.14.2	Quantitative Determination of Estrogen (E ₂)	130
3.14.2.1	Principle of E ₂ Assay	130
3.14.2.2	Reagents for E ₂ Assay	132
3.14.2.3	Procedure for E ₂ Assay	132
3.14.2.4	Calculation of E ₂ Assay Results	133
3.14.3	Quantitative Determination of Luteinizing Hormone (LH)	133
3.14.3.1	Principle of LH Assay	133
3.14.3.2	Reagents for LH Determination	134
3.14.3.3	Assay Procedure for LH	134
3.14.3.4	Calculation of LH Results	135
3.14.4	Determination of Follicle Stimulating Hormone (FSH) Activity	135
3.14.4.1	Principle of FSH Analysis	135
3.14.4.2	Reagents for FSH Assay	136
3.14.4.3	Preparation of Wash Solution	136
3.14.4.4	FSH Assay Procedure	136
3.14.4.5	Calculation of FSH Assay Results	137
3.15	Determination of Endometrial Proteins Level	137
3.15.1	Progesterone Associated Endometrial Protein (PAEP) in the Serum	137
3.15.1.1	Principle of PEAP Immunoassay	138
3.15.1.2	Reagents for PAEP Assay	138
3.15.1.3	Procedure for PAEP Assay	139
3.15.1.4	Calculation of Results of PAEP	139
3.15.2	In-vitro Quantitative Measurement of Leukemia Inhibitory Factor (LIF)	140

3.15.2.1	Principle of LIF Assay	140
3.15.2.2	Reagents for LIF Determination	140
3.15.2.3	Procedure for LIF Assay	142
3.15.2.4	Calculation of LIF Results	143
3.15.3	Quantitative Determination of Prolactin	144
3.15.3.1	Principle of Prolactin ELISA Assay	144
3.15.3.2	Reagents for Prolactin Assay	144
3.15.3.3	Procedure for Prolactin Assay	145
3.15.3.4	Calculation of LIF Results	145
3.15.4	Quantitative Determination of Sex Hormone Binding Globulin (SHBG)	146
3.15.4.1	Principle of SHBG Determination	146
3.15.4.2	Reagents for the Determination of SHBG	146
3.15.4.3	Procedure for SHBG Assay	147
3.15.4.4	Calculation of SHBG Results	149
3.16	Assessment of Inflammatory Markers	149
3.16.1	Nuclear Factor Kappa B (NF- κ B)	149
3.16.1.1	Principle for the Determination of NF- κ B	149
3.16.1.2	Reagents for NF- κ B Assay	150
3.16.1.3	Procedure for the Determination of NF- κ B	150
3.16.1.4	Calculation of NF- κ B Elisa Results	151
3.16.2	Determination of Tumor Necrosis Factor- α (TNF- α)	151
3.16.2.1	Principle for the Quantitative Determination TNF- α	151
3.16.2.2	Reagents for TNF- α Elisa Assay	151

3.16.2.3	Procedure for TNF- α Elisa Assay	152
3.16.2.4	Calculation of TNF- α Elisa Results	152
3.16	Liver and Kidney Function Indices	153
3.17.1	Estimation of Aspartate Transaminases (AST)	153
3.17.1.1	Composition of Reagent used for AST Analysis	153
3.17.1.2	Procedure for AST Assay	153
3.17.1.3	Calculation of AST Activity	154
3.17.2	Estimation of Alanine Aminotransferase (ALT)	154
3.17.2.1	Principle of ALT Estimation	154
3.17.2.2	Procedure for ALT Assay	154
3.17.2.3	Standard Calibration Curve for ALT Activity	155
3.17.3	Calculation of AST/ALT Ratio	157
3.17.4	Estimation of Alkaline Phosphatase (ALP)	157
3.17.4.1	Principle of ALP Determination	157
3.17.4.2	Composition and Preparation of the Reagents	157
3.17.4.3	Procedure for the ALP Assay	157
3.17.4.4	Calculation of ALP Activity	157
3.17.5	Estimation of Total Protein in Serum and Liver Homogenate	158
3.17.5.1	Principle of Total Protein Assay	158
3.17.5.2	Reagents for Total Protein Estimation	158
3.17.5.3	Standard Protein (BSA) Curve	158
3.17.5.4	Procedure for Total Protein Estimation in Samples	159
3.17.6	Gamma Glutamyl Transferase (γ GT) Determination	159

3.17.6.1	Reagents used for γ GT Assay	160
3.17.6.2	Procedure for γ GT Assay	160
3.17.6.3	Calculation of γ GT Activity	160
3.18	Determination of Kidney Function Indices	161
3.18.1	Quantitative Determination of Cystatin C	161
3.18.1.1	Principle of Cystatin C Assay	161
3.18.1.2	Reagents Preparation for Cystatin C Determination	161
3.18.1.3	Procedure for Cystatin C Assay	161
3.18.1.4	Calculation of Cystatin C Results	162
3.18.2	Creatinine Determination in Tissues	162
3.18.2.1	Reagent Composition for Creatinine Determination	162
3.18.2.2	Procedure for Creatinine Analysis	163
3.18.2.3	Calculation of Creatinine Concentration in Sample	163
3.18.3	Determination of Urea Concentration	163
3.18.3.1	Reagents for the Determination of Urea	164
3.18.3.2	Procedure for the Assay of Urea	164
3.18.3.3	Calculation of Urea Concentration	164
3.18.4	Urea BUN/ Creatinine Ratio	165
3.19	Assessment of Oxidative Stress Biomarkers	165
3.19.1	Catalase Activity (CAT) Determination	165
3.19.1.1	Preparation of Reagents for CAT Assay	165
3.19.1.2	Assay Procedure for CAT Assay	165
3.19.1.3	Calculation of CAT Activity	166

3.19.2	Determination of Reduced Glutathione (GSH) Level	166
3.19.2.1	Reagents Preparation for GSH Analysis	166
3.19.2.2	GSH Standard Curve Preparation	167
3.19.2.3	Procedure for the Determination of GSH in Samples	167
3.19.3	Estimation of Glutathione Peroxidase (GPx) Activity	167
3.19.3.1	Reagents Preparation for GPx Activity Assay	168
3.19.3.2	Procedure for GPx Analysis	168
3.19.3.3	Calculation of GPx Activity	169
3.19.4	Estimation of Glutathione-S-Transferase (GST) Activity	169
3.19.4.1	Reagents Preparation for GST Assay	169
3.19.4.2	Procedure for GST Analysis	170
3.19.4.3	Calculations for the Determination of GST Activity	170
3.19.5	Determination of Superoxide Dismutase (SOD) Activity	170
3.19.5.1	Reagents Preparation for SOD Assay	171
3.19.5.2	Protocol for Sample Preparation	171
3.19.5.3	Calculation of SOD Reaction	171
3.19.6	Lipid Peroxidation (LPO) Assay	171
3.19.6.1	Reagents Preparation for LPO Assay	172
3.19.6.2	Procedure of LPO Assay	172
3.19.6.3	Calculation of MDA	173
3.20	Statistical Analysis	173
	Endnotes	174

Chapter Four: Results and Discussion of Findings

4.1	Analysis of Cross-Sectional Study using Questionnaire	177
4.1.1	Demographics Characteristics of Respondents	177
4.1.2	Respondents' Knowledge and Awareness of Contraceptive Methods and Use	180
4.1.3	Prevalence of Side Effects from Various Contraceptive Methods	187
4.2	Physical Observation of the Experimental Model (Wistar rats) before, during and after Treatments	191
4.3	Comparative Evaluation of the Effect of Postinor 2 on the Body Weights of Wistar Rats Before and After Treatments	193
4.4	Effect of Postinor 2 Treatment on Rats' Estrous Cycle	195
4.4.1	Visual Assessment of the Effect of Postinor 2 on Rats' Estrous Cycle	195
4.4.2	Cytological Assessment of the Effect of Postinor 2 on the Estrous Cycle	195
4.5	Effect of Postinor 2 Treatment on Relative Organ Weights	197
4.5.1	Effect on Relative Uterus Weight	197
4.5.2	Effect of Postinor 2 Treatment on Relative Ovary Weight	199
4.5.3	Effect of Postinor 2 Treatment on Relative Liver Weight	201
4.5.4.	Effect of Postinor 2 on Relative Kidney Weight	203
4.6	Histopathological Examination of the Harvested Tissues for Effect of Postinor 2 Intake	205
4.6.1	Histopathological Examination of the Uterus	205
4.6.2	Histopathological Examination of the Ovary	211
4.6.3	Histopathological Examination of the Liver	218
4.6.4	Histopathological Examination of the Kidney	225
4.7	Effect of Postinor 2 Intake on Progesterone (P4) Level in the Serum of Wistar Rats	232
4.8	Effect of Postinor 2 Intake on Estrogen (E ₂) Level in the Serum of Wistar Rats	234
4.9	Effect of Postinor 2 Intake on Serum Luteinizing Hormone (LH)	

	Concentration of Wistar Rats	236
4.10	Effect of Postinor 2 Intake on the Serum Concentration of Follicle Stimulating Hormone (FSH) of Wistar Rats	238
4.11	Effect of Postinor 2 Intake on the Serum Concentration of Progesterone Associated Endometrial Protein (PAEP) of Wistar Rats	240
4.12	Effect of Postinor 2 Intake on the Serum Concentration of Leukemia Inhibitory Factor (LIF)	242
4.13	Effect of Postinor 2 Intake on the Serum Concentration of Prolactin (PRL)	244
4.14	Effect of Postinor 2 Intake on the Concentration of Sex Hormone-Binding Globulin (SHBG) in the Serum	246
4.15	Effect of Postinor 2 Intake on the Concentration of Nuclear Factor -Kappa B (NF- κ B) in the Serum and Reproductive Organs of Wistar Rats	248
4.16	Effect of Postinor 2 Intake on the Concentration of Tumor Necrosis Factor-Alpha (TNF- α) in the Serum and Reproductive Organs of Wistar Rats	252
4.17	Effect of Postinor 2 Intake on Liver Function Indices	256
4.17.1	Effect on Postinor 2 Intake on Aspartate Transferase (AST) in the Serum and Liver of Wistar Rats	256
4.17.2	Effect of Postinor 2 Intake on Alanine Aminotransferase (ALT) Activity in the Serum and Liver of Wistar Rats	261
4.17.3	Effect of Postinor 2 Intake on Aspartate Transferase (AST): Alanine Aminotransferase (ALT) Ratio in the Serum and Liver of Wistar Rats	265
4.17.4	Effect of Postinor 2 Intake on Alkaline Phosphatase (ALP) Activity in the Serum and Liver of Treated Rats Compared with Control	268
4.17.5	Effect of Postinor 2 Intake on Total Protein	271
4.17.6	Effect of Postinor 2 Intake on γ -Glutamyl transferase Concentration in the Serum and Liver of Wistar Rats	274
4.18	Effect of Postinor 2 Intake on Kidney Function	278
4.18.1	Effect of Postinor 2 Intake on Cystatin C Concentration in the Serum of Wistar Rats	278

4.18.2	Effect of Postinor 2 Intake on the Level of Creatinine (Cr) in the Kidney of Wistar Rats	281
4.18.3	Effect of Postinor 2 Intake on the Level of Urea in the Serum and Kidney of Wistar Rats	283
4.18.4	Determination of BUN: Creatinine Ratio	286
4.19	Assessment of Postinor 2 Intake on Oxidative stress Biomarkers	288
4.19.1	Effects of Treatment on Catalase Activity in Reproductive and Vital Organs of Wistar Rats	288
4.19.2	Effects of Treatment on the Concentration of Reduced Glutathione (GSH) in Reproductive and Vital Organs of Wistar Rats	293
4.19.3	Effects of Postinor 2 Intake on the Concentration of Glutathione Peroxidase (GPx) in Reproductive and Vital Organs of Wistar Rats	298
4.19.4	Effects of Postinor 2 on the Concentration of Glutathione-S-Transferase in Reproductive and Vital Organs of Wistar Rats	309
4.19.5	Effects of Postinor 2 on the Activity of Superoxide Dismutase (SOD) in Reproductive and Vital Organs of Wistar Rats	309
4.19.6	Effects of Postinor 2 Intake on the level of Malondialdehyde (MDA) in Reproductive and Vital Organs of Wistar Rats	314
4.20	Discussion of Findings	320
	Endnotes	345
	Chapter Five: Conclusion	
5.1	Summary of Findings	358
5.2	Conclusion	359
5.3	Recommendations	361
5.4	Contribution to Knowledge	362
5.5	Suggested Areas for Further Research	362

Bibliography	364
Appendix	399
Biodata	423
The University Compliance Form	418

List of Tables

Table	Title	Page
2.1	Comparison of Adverse Effects of LNG and UPA	55
3.1	Experimental Design	123
3.2	Standard Curve for PAEP	140
3.3	Dilution Procedure for Standard and Sample Diluent in LIF Assay	142
3.4	Preparation of Reagents for SHBG Assay	147
3.5	Procedure for AST Assay	154
3.6	Procedure for ALT Standards	156
3.7	Protocol for Protein Standard Curve Preparation	159
3.8	Procedure for the Determination of Cystatin C	161
3.9	Procedure for the Assay of Urea	164
3.10	GSH Standard Curve Protocol	167
3.11	Glutathione S-Transferase Assay Medium	170
4.1	Distribution of Side Effects Observed from the Use of Various Contraceptives	190
4.2	Observation of Wistar Rats before, during and after Treatments	192

4.3	Cytological Assessment of the Estrus Cycle in Animals Treated with Postinor 2 Compared with Control	196
-----	---	-----

List of Figures

Figure	Title	Page
2.1	Effectiveness of Emergency Contraceptive Pills (ECPs)	34
2.2	Chemical Structure of Levonorgestrel	38
2.3a	Postinor 2 Tablet	42
2.3b	Plan B Levonorgestrel Tablet	42
2.4a	Postpill Tablet (1 Tablet of Levonorgestrel 1.5 mg)	43
2.4b	Afterpill Tablet	43
2.5	Chemical Structure of Ullipristal Acetate	48
2.6	Mechanism of Action of Ulipristal Acetate (UPA)	50
2.7	Ella One, a 30 mg UPA Tablet	52
2.8a	The Chemical Structure of Ethinylestradiol	57
2.8b	Ethinyl Estradiol 0.05 mg Tablet	57
2.9	The Female Reproductive Organ	62
2.10	The Menstrual Cycle	66
2.11	The Parts of the Uterine Tube	68
2.12	The Immunoregulatory Effects of Glycodelin on Multiple Immune Cells Including Monocyte-Macrophages, Dendritic Cells (Dcs), B Cells, Natural Killer (NK) Cells, and T Cells	74
2.13	Stages of Blastocyst Implantation	80
2.14	Chemical Structure of Progesterone	84
2.15	Roles of Growth Factors in Implantation	90

2.16	Effect of LH in the Body	94
4.1	Age Distribution of Respondents	178
4.2	Marital Status of Respondents	179
4.3	Response of Participants to Question on the Use of Contraception	181
4.4	Distribution of Contraceptive Use among the Different Age Groups	182
4.5	Response to Question on the Specific Method of Contraception used	183
4.6	Specific Type of Pills used by Respondents	185
4.7	Frequency of Pills used by Participants	186
4.8	Side Effects Observed by Respondents from the use of Contraceptives	188
4.9	Side Effects Observed by Respondents from the use of Contraceptives	189
4.10	Effect of Postinor 2 on the Body Weights of Animals	189
4.11a	Effect of Postinor 2 on the Relative Uterus Weight of Treated Wistar Rats Compared with Control	198
4.11b	The Relative Ovary Weights of Control and Treated Groups	200
4.11c	Effect on Postinor 2 on the Relative Liver Weights	202
4.11d	The Effect of Postinor 2 on Relative Kidney Weights	204
4.12	Effect on Postinor 2 Intake on the Serum Concentration of Progesterone	233
4.13	Effect of Postinor 2 Intake on the Serum Concentration of Estrogen	235
4.14	Effect of Postinor 2 Intake on the Serum Concentration of Luteinizing Hormone	237
4.15	Effect of Postinor 2 Intake on the Serum Concentration of Follicle Stimulating Hormone	239
4.16	Effect of Postinor 2 Intake on the Serum Concentration of Progestagen Associated Endometrial Protein (PAEP)	241
4.17	Effect of Postinor 2 Intake on the Serum Concentration of Leukemia Inhibitory Factor (LIF)	243

4.18	Effect of Postinor 2 Intake on the Serum Concentration of Prolactin	245
4.19	Effect of Postinor 2 Intake on the Serum Concentration of Sex Hormone-Binding Globulin	247
4.20a	Effect of Postinor 2 Intake on the Serum Concentration of Nuclear Factor-Kappa B	244
4.20b	Effect of Postinor 2 Intake on the Concentration of Nuclear Factor -Kappa B in the Uterus of Wistar Rats	250
4.20c	Effect of Postinor 2 Intake on the Concentration of Nuclear Factor -Kappa B in the Ovary of Wistar Rats	251
4.21a	Effect of Postinor 2 Intake on the Serum Concentration of Tumor Necrosis Factor-alpha	253
4.21b	Effect of Postinor 2 Intake on the Concentration of Tumor Necrosis Factor-alpha in the Uterus	254
4.21c	Effect of Postinor 2 Intake on the Concentration of Tumor Necrosis Factor-alpha in the Ovary	255
4.22a	Aspartate Aminotransferase (AST) Standard Curve	258
4.22b	Effect of Postinor 2 Intake on Aspartate Aminotransferase (AST) Activity in the Serum of Wistar Rats	259
4.22c	Effect of Postinor 2 Intake on Aspartate Aminotransferase (AST) Activity in the Liver of Wistar Rats	260
4.23a	Alanine Transaminase (ALT) Standard Curve	262
4.23b	Effect of Postinor 2 Intake on Alanine Transaminase (ALT) Activity in the serum of Wistar Rats	263
4.23c	Effect of Postinor 2 Intake on Alanine Transaminase (ALT) Activity in the Liver of Wistar Rats	264
24a	AST: ALT Ratio in the Serum of Wistar Rats Treated with Postinor 2 Once Weekly, Twice Weekly and Control	266
24b	AST: ALT Ratio in the Liver of Wistar Rats Treated with Postinor 2 Once Weekly, Twice Weekly and Control	267
4.25a	Effect of Postinor 2 Intake on Alkaline Phosphatase (ALP) Activity in the Serum	

of Wistar Rats	269
4.25b Effect of Postinor 2 Intake on Alkaline Phosphatase (ALP) Activity in the Liver of Wistar Rats	270
4.26a Effect of Postinor 2 Intake on Total Protein Concentration in the Liver of Wistar Rats	272
4.26b Effect of Postinor 2 Intake on Total Protein Concentration in the Kidney of Wistar Rats	273
4.27a Effect of Postinor 2 Intake on γ -Glutamyl Transferase Activity in Serum (U/L) of Wistar Rats	276
4.27b Effect of Postinor 2 Intake on γ -Glutamyl Transferase Concentration in Liver (U/L) of Wistar Rats	277
4.28a Standard Curve for the Calibration of Cystatin C	279
4.28b Effect of Postinor 2 Intake on Cystatin C Concentration in the Serum of Wistar Rats	280
4.29 Effect of Postinor 2 Intake on the Concentration of Creatinine in the Kidney of Wistar Rats	282
4.30a Effect of Postinor 2 Intake on the Concentration of Urea in the Serum of Wistar Rats	284
4.30b Effect of Postinor 2 Intake on the Concentration of Urea in the Kidney of Wistar Rats	285
4.31 Effect of Postinor 2 Intake on the Level of Blood Urea Nitrogen: Creatinine Ratio (BUN: Cr) in the Kidney of Wistar Rats	287
4.32a Effect of Postinor 2 Intake on Catalase Activity in Uterus of Wistar Rats	289
4.32b Effect of Postinor 2 Intake on Catalase Activity in Ovary of Wistar Rats	290
4.32c Effect of Postinor 2 Intake on Catalase Activity in Liver of Wistar Rats	291
4.32d Effect of Postinor 2 Intake on Catalase Activity in Kidney of Wistar Rats	292
4.33a Effect of Postinor 2 Intake on Reduced Glutathione (GSH) Concentration in Uterus of Wistar Rats	295
4.33b Effect of Postinor 2 Intake on Reduced Glutathione (GSH) Concentration in	

Ovary of Wistar Rats	296
4.33c Effect of Postinor 2 Intake on Reduced Glutathione (GSH) Concentration in Liver of Wistar Rats	297
4.33d Effect of Postinor 2 Intake on Reduced Glutathione (GSH) Concentration in Kidney of Wistar Rats	298
4.34a Effect of Postinor 2 Intake on Glutathione Peroxidase (GPx) Activity in Uterus of Wistar Rats	300
4.34b Effect of Postinor 2 Intake on Glutathione Peroxidase (GPx) Activity in Ovary of Wistar Rats	301
4.34c Effect of Postinor 2 Intake on Glutathione Peroxidase (GPx) Activity in Liver of Wistar Rats	302
4.34d Effect of Postinor 2 Intake on Glutathione Peroxidase (GPx) Activity in Kidney of Wistar Rats	303
4.35a Effect of Postinor 2 Intake on Glutathione-S-Transferase (GST) Activity in Uterus of Wistar Rats	305
4.35b Effect of Postinor 2 Intake on Glutathione-S-Transferase (GST) Activity in Ovary of Wistar Rats	306
4.35c Effect of Postinor 2 Intake on Glutathione-S-Transferase (GST) Activity in Liver of Wistar Rats	307
4.35d Effect of Postinor 2 Intake on Glutathione-S-Transferase (GST) Activity in Kidney of Wistar Rats	308
4.36a Effect of Postinor 2 Intake on Superoxide Dismutase (SOD) Activity in Uterus of Wistar Rats	310
4.36b Effect of Postinor 2 Intake on Superoxide Dismutase (SOD) Activity in Ovary of Wistar Rats	311
4.36c Effect of Postinor 2 Intake on Superoxide Dismutase (SOD) Activity in Liver of Wistar Rats	312
4.36d Effect of Postinor 2 Intake on Superoxide Dismutase (SOD) Activity in Kidney of Wistar Rats	313
4.37a Effect of Postinor 2 Intake on Malondialdehyde (MDA) Concentration in Uterus of Wistar Rats	316

4.37b	Effect of Postinor 2 Intake on Malondialdehyde (MDA) Concentration in Ovary of Wistar Rats	317
4.37c	Effect of Postinor 2 Intake on Malondialdehyde (MDA) Concentration in Liver of Wistar Rats	318
4.37d	Effect of Postinor 2 Intake on Malondialdehyde (MDA) Concentration in Kidney of Wistar Rats	319

Do Not Copy, Lead City University, Nigeria

List of Plates

Plate	Title	Page
4.1	Photomicrographs of Thin Sections of Uterus Tissues Harvested from the Control Group I	206
4.2	Photomicrographs of Thin Sections of Uterus Tissues Harvested from the Control Group II	207
4.3	Photomicrographs of Thin Sections of Uterus Tissues Harvested from the Once Weekly Treated Group I	208
4.4	Photomicrographs of Thin Sections of Uterus Tissues Harvested from the Once Weekly Treated Group II	209
4.5	Photomicrographs of Thin Sections of Uterus Tissues Harvested from the Twice Weekly Treated Group	210
4.6	Photomicrographs of Thin Sections of Ovary Tissues Harvested from the Control Group I	212
4.7	Photomicrographs of Thin Sections of Ovary Tissues Harvested from the Control Group II	213
4.8	Photomicrographs of Thin Sections of Ovary Tissues Harvested from the Once Weekly Treated Group I	214
4.9	Photomicrographs of Thin Sections of Ovary Tissues Harvested from the Once Weekly Treated Group II	215
4.10	Photomicrographs of Thin Sections of Ovary Tissues Harvested from the Twice Weekly treated Group I	216
4.11	Photomicrographs of Thin Sections of Ovary Tissues Harvested from the Twice Weekly Treated Group II	217
4.12	Photomicrographs of Thin Sections of Liver Tissues Harvested from Control Group I	219
4.13	Photomicrographs of Thin Sections of Liver Tissues Harvested from Control Group II	220

4.14	Photomicrophs of Thin Sections of Liver Tissues Harvested from Once Weekly Treated Group I	221
4.15	Photomicrophs of Thin Sections of Liver Tissues Harvested from Once Weekly Treated Group II	222
4.16	Photomicrophs of Thin Sections of Liver Tissues Harvested from Twice Weekly Treated Group I	223
4.17	Photomicrophs of Thin Sections of Liver Tissues Harvested from Twice Weekly Treated Group II	224
4.18	Photomicrophs of Thin Sections of Kidney Tissues Harvested from Control Group I	226
4.19	Photomicrophs of Thin Sections of Kidney Tissues Harvested from Control Group II	227
4.20	Photomicrophs of Thin Sections of Kidney Tissues Harvested from Once Weekly Treated Group I	228
4.21	Photomicrophs of Thin Sections of Kidney Tissues Harvested from Once Weekly Treated Group II	229
4.22	Photomicrophs of Thin Sections of Kidney Tissues Harvested from Twice Weekly Treated Group I	230
4.23	Photomicrophs of Thin Sections of Kidney Tissues Harvested from Twice Weekly Treated Group II	231

List of Acronyms

Acronym	Meaning
LNG	Levonorgestrel
NSDUH	The National Survey on Drug Use and Health Substance Abuse
SAMHSA	Mental Health Services Administration
SUD	Substance Use Disorder
UNODC	United Nations Office on Drugs and Crime
COCs	Combined oral contraceptives
OTC	Over the Counter
ECPs	Emergency Contraceptive Pills
UPA	Ulipristal Acetate
IUD	Intrauterine Contraceptive Device
RIF	Recurrent Implantation Failure
DES	Estrogen Diethylstilbestrol
NDLEA	National Drug Law Enforcement Agency
STDs	Sexually Transmitted Diseases
WHO	World Health Organization
ELISA	Enzyme Linked Immunosorbent Assay
PAEP	Progesterone Associated Endometrial Protein
LIF	Leukemia Inhibitory Factor
PRL	Prolactin

SHBG	Sex Hormone - Binding Globulin
FSH	Follicle-Stimulating Hormone
LH	Luteinizing Hormone
PRAC	Pharmacovigilance Risk Assessment Committee
LIF	Leukemia-inhibitory factor
IVF-ET	In Vitro Fertilization, and Embryo Transfer
PCOS	Polycystic Ovary Syndrome
MFI	Multiple Failures of Implantation
GnRH	Gonadotropin-releasing hormone
GST	Glutathione-S-Transferase
DTNB	Dinitrothiocyanobenzene
GSH	Reduced Glutathione
GPx	Glutathione Peroxidase
CAT	Catalase

Do Not Copy, Lead City University, Nigeria